Graciela Molinero

Graciela Molinero

Auto-generated profile, based on publicly available information

Graciela Molinero

Council of Epidemiology and Cardiovascular Prevention, Argentine Society of Cardiology, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2022 in Advances in Respiratory Medicine
Verified
Journal Article
Open access
LBLeandro Barbagelata
Leandro Barbagelata
WMWalter Masson
Walter Masson
IBIgnacio Bluro
Ignacio Bluro
LLLorenzo Lobo
Lorenzo Lobo
DIDiego Iglesias
Diego Iglesias
GMGraciela Molinero
Graciela Molinero
Introduction: Several studies have evaluated the relation between variables of cardiopulmonary exercise testing (CPET) and major clinical events in pulmonary hypertension (PH) patients, although the results were conflicting. The main objective of this study was to investigate the prognostic value of the CPET derived parameters on all-cause mortality or urgent transplantation in PH patients. Material and Methods: A meta-analysis of time-to-event outcomes were performed from observational studies that evaluated the predictive value of CEPT-related variables [peak oxygen uptake (VO₂) and the ventilation to CO₂ production slope (VE/VCO₂)] in PH patients, reporting data from mortality or urgent transplantation, after searching the PubMed/MEDLINE, Embase, Science Direct, Scopus, Google Scholar, and Cochrane databases. A random-effects meta-analysis model was then applied. Results: Nine eligible studies, including 986 patients, were identified and considered eligible for the quantitative analyses. This meta-analysis showed that high peak VO₂ was associated with a lower mortality or transplant occurrence (HR: 0.81; 95% CI: 0.78–0.85, I2 = 29%). In addition, high VE/VCO₂ slope was associated with a higher incidence of the primary endpoint (HR: 1.04; 95% CI: 1.02-1.06, I2 = 78%). The sensitivity analysis showed that the results were robust. Conclusions: Our data suggest that in a population with PH the CPET-related variables have predictive capacity regarding mortality and the risk of transplantation. Future studies should establish the best cut-off points for these CPET-related variables.

1 November 2019 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
WMWalter Masson
Walter Masson
LLLorenzo Lobo
Lorenzo Lobo
GMGraciela Molinero
Graciela Molinero
EREmiliano Rossi
Emiliano Rossi
Different strategies have been proposed for the cardiovascular risk management of patients with psoriasis. To estimate the cardiovascular risk and evaluate two cardiovascular prevention strategies in patients with psoriasis, analyzing which proportion of patients would be candidates to receive statin therapy. A retrospective cohort was selected from a secondary database. All patients >18 years with psoriasis without cardiovascular disease or lipid-lowering treatment were included. The atherosclerotic cardiovascular disease calculator (2018 American College of Cardiology/American Heart Association guidelines) and the Systematic Coronary Risk Evaluation risk calculator (2016 European Society of Cardiology/European Society of Atherosclerosis guidelines) were calculated. The SCORE risk value was adjusted by a multiplication factor of 1.5. The recommendations for the indication of statins suggested by both guidelines were analyzed. A total of 892 patients (mean age 59.9±16.5 years, 54.5% women) were included. The median atherosclerotic cardiovascular disease calculator and Systematic Coronary Risk Evaluation values were 13.4% (IQR 6.1-27.0%) and 1.9% (IQR 0.4-5.2), respectively. According to the atherosclerotic cardiovascular disease calculator, 20.1%, 11.0%, 32.9%, and 36.4% of the population was classified at low, borderline, moderate, or high risk. Applying the Systematic Coronary Risk Evaluation, 26.5%, 42.9%, 20.8%, and 9.8% of patients were stratified as having low, moderate, high, or very high risk, respectively. The proportion of subjects with statin indication was similar using both strategies: 60.1% and 60.9% for the 2018 American College of Cardiology/American Heart Association and 2016 European Society of Cardiology/European Society of Atherosclerosis guidelines, respectively. This was a secondary database study. Data on the severity of psoriasis and pharmacological treatments were not included in the analysis. This population with psoriasis was mostly classified at moderate-high risk and the statin therapy indication was similar when applying the two strategies evaluated.

1 May 2021 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
WMWalter Masson
Walter Masson
LLLorenzo Lobo
Lorenzo Lobo
GMGerardo Masson
Gerardo Masson
GMGraciela Molinero
Graciela Molinero
PCPaola Casciato
Paola Casciato

3 July 2021 in Acta Cardiologica
Verified
Journal Article
Closed access
WMWalter Masson
Walter Masson
LLLorenzo Lobo
Lorenzo Lobo
LBLeandro Barbagelata
Leandro Barbagelata
ACAugusto Maria Lavalle Cobo
Augusto Maria Lavalle Cobo
GMGraciela Molinero
Graciela Molinero
Given the complex aetiology and a limited amount of evidence, the medical treatment (including statin use) of myocardial infarction with non-obstructive coronary artery disease (MINOCA) remains unc...

28 July 2025 in Revista Argentina de Cardiologia
Verified
Journal Article
Open access
PDF file
LLLorenzo Lobo
Lorenzo Lobo
WMWalter Masson
Walter Masson
GMGraciela B. Molinero
Graciela B. Molinero
GGGustavo Giunta
Gustavo Giunta
ACAugusto Maria Lavalle Cobo
Augusto Maria Lavalle Cobo
MGMariano Giorgi
Mariano Giorgi
Background: Risk stratification in type 2 diabetes mellitus (DM2) patients constitutes a real clinical challenge. Objectives: 1) To stratify cardiovascular risk in a population with DM2 in primary prevention, using different risk scores; 2) To describe the prevalence of atherosclerotic carotid plaque (ACP); 3) To analyze the correlation and concordance between the different risk scores; and 4) To evaluate the discriminative capacity of the different scores to identify the presence or absence of ACP. Methods: Observational, cross-sectional, multicenter study. Patients with DM2 in primary prevention without lipid-lowering treatment were included. The following risk scores were calculated: Framingham scores for cardiovascular disease (FrCVD) and for coronary heart disease (FrCHD), the 2018 ACC/AHA (AHA2018), PREVENT (AHA2023) and Diabetes-2 (S2-DBT) scores, and UKPDS scores for fatal coronary heart disease (UKPDS-FCHD), non-fatal coronary heart disease (UKPDS-NFCHD), fatal stroke (UKPDS-FS) and non-fatal stroke (UKPDS-NFS). Correlation and concordance between them were evaluated. the discriminative capacity of the different scores for PAC prediction analyzed using ROC curves. Results: A total of 170 patients were included in the study, (mean age of 61.2±10.8 years, 58.8% men). The proportion of patients classified as at least high risk was 71.2%, 39.9%, 43.6%, 23.9%, 20.9%, 53.4%, 9.8% and 49.7% when the FrCVD, FrCHD, UKPDS-NFCHD, UKPDS-FCHD, UKPDS-NFS, AHA2018, AHA2023S and 2-DBT scores, respectively, were applied. No patient was classified with risk ≥20 % when using UKPDS-FS score. A good correlation was observed between all scores assessed (Spearman´s rho values between 0.64 and 0.98). The overall agreement between the scores was fair (Fleiss Kappa coefficient of 0.38). The prevalence of ACP was 50.6%, higher in the upper risk strata of all the scores evaluated. The analysis of the ROC curves showed a very good predictive capacity of all the scores for ACP detection. Conclusion: Cardiovascular risk was considerable for most of the scores evaluated, with an adequate correlation, but a fair concordance between the different scores. A very good predictive ability of all scores for ACP detection was observed.

15 April 2025 in Revista Argentina de Cardiologia
Verified
Journal Article
Open access
PDF file
WMWalter Masson
Walter Masson
LLLorenzo Lobo
Lorenzo Lobo
ACAugusto Maria Lavalle Cobo
Augusto Maria Lavalle Cobo
GMGraciela Molinero
Graciela Molinero
Introducción y objetivos: La asociación entre el uso de colchicina y la incidencia de infarto agudo de miocardio (IAM) es heterogénea. El objetivo principal del presente estudio fue evaluar el efecto de la colchicina sobre la incidencia de IAM. La evaluación de la incidencia de accidente cerebrovascular (ACV) y la mortalidad cardiovascular fueron los objetivos secundarios. Material y métodos: Se realizó un metaanálisis de estudios aleatorizados que evaluaron el uso de colchicina en pacientes con enfermedad aterosclerótica y que reportaron los eventos cardiovasculares, luego de una búsqueda en las bases de datos PubMed/MEDLINE, Embase, Scielo y Cochrane Controlled Trials. Se utilizó un modelo de efectos fijos o aleatorios según la heterogeneidad observada. Resultados: Se seleccionaron para el análisis del punto final primario 7 estudios (con un total de 5966 sujetos en la rama colchicina y 5948 pacientes en la rama control). Este metaanálisis demostró que la terapia con colchicina se asoció a un menor riesgo de IAM (OR: 0,76, IC 95%: 0,62-0,92; I2 =15%). Asimismo, se observó una reducción significativa en la incidencia de ACV, sin un efecto significativo en la mortalidad cardiovascular, con la intervención farmacológica. Conclusión: El uso de colchicina en pacientes con enfermedad cardiovascular aterosclerótica se asoció a una reducción significativa en la incidencia de IAM. La incorporación de la colchicina dentro del arsenal terapéutico de la enfermedad cardiovasculardeberá ser considerada por las futuras guías de práctica clínica.